 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wedbush reissued their outperform rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report) in a research report sent to investors on Friday, Benzinga reports. The brokerage...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Earns "Outperform" Rating from Wedbush

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MoonLake Immunotherapeutics (MLTX Research Report...

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and BioNTech SE (BNTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report)  Lifesci Capital increased their FY2023 EPS estimates for MoonLake Immunotherapeutics in a research note issued on Tuesday...

MoonLake Immunotherapeutics (NASDAQ:MLTX) to Post FY2023 Earnings of ($0.88) Per Share, Lifesci Capital Forecasts

MoonLake Immunotherapeutics (NASDAQ:MLTX  Get Free Report) had its price objective boosted by stock analysts at Guggenheim from $70.00 to $77.00 in a note issued to investors on Wednesday...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Increased to $77.00 by Analysts at Guggenheim

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing...

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on MoonLake Immunotherapeutics (MLTX Research Report) yesterday and set a price...

Stifel Nicolaus Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on MoonLake Immunotherapeutics (MLTX Research Report), with a price target of $7...

Positive Phase II Study Results Bolster Buy Rating for MoonLake Immunotherapeutics

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody sonelokimab in active psoriatic arthritis First placebo-controlled randomized trial in active psoriatic arthritis (PsA...

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody  sonelokimab in active psoriatic arthritis

MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report)  Research analysts at Cantor Fitzgerald cut their FY2024 earnings per share (EPS) estimates for shares of MoonLake...

Cantor Fitzgerald Brokers Reduce Earnings Estimates for MoonLake Immunotherapeutics (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX  Get Free Report) traded down 2.9% during mid-day trading on Tuesday . The stock traded as low as $58.76 and last traded at $58.79. 97,221 shares...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 2.9%

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

Watchers	503
52-Wk Low	$9.08
52-Wk High	$63.40

Market Cap	$2.88B
Volume (M)	324,299.00
52-Wk High	$63.40
52-Wk Low	$9.08

Current Price	$47.23
Prev Close	$46.10
Open	$45.86
Dividend Yield	0.00%
50-Day Moving Average	$49.66
Beta	0.54
Avg. Volume	994,870.10
PE Ratio	-50.03

52-Week High	$63.40
52-Week Low	$9.08
Market Capitalization	$2.88B
EPS	-$0.944
Price to Book	5.95
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-46.96

MLTX MoonLake Immunotherapeutics - Ordinary Shares - Class A

About

Feed

News

Sentiment

Fundamentals